Showing 6101-6110 of 7115 results for "".
- Dermira Prices Initial Public Offeringhttps://practicaldermatology.com/news/20141003-dermira_prices_initial_public_offering/2459096/Dermira will price its initial public offering of 7,812,500 shares of common stock at a price to the public of 16 dollars per share. The shares are expected to begin trading on The NASDAQ Global Select Market on October 3, 2014 under the symbol DERM.Citigroup and Leerink Partners are acti
- Website Launches for Those Suffering from Acne Scarshttps://practicaldermatology.com/news/20141003-website_launches_for_those_suffering_from_acne_scars/2459097/A new website has launched to help those who suffer from the physical and emotional impacts of acne scarring. “A Scar Free Me” is the first of its kind online community that offers free resources and support for people coping with the aftermath of acne. Visitors can consult with skin car
- Teledermatology App Teams Up with Dermatologistshttps://practicaldermatology.com/news/20141002-teledermatology_company_teams_up_with_dermatologists/2459098/A new teledermatology app is partnering with board- and state-certified dermatologists to assist patients with on-the-spot information regarding the detection and evaluation of skin disease in early stages. Having launched already in 13 states, Klara has partnered up with Dr. Mark Kaufmann, MD, Asso
- Ranbaxy Launches Absorica 25mg and 35mg Capsuleshttps://practicaldermatology.com/news/20141001-ranbaxy_launches_absorica_25mg_and_35mg_capsules/2459099/Ranbaxy Laboratories Inc., a wholly owned subsidiary of Ranbaxy Laboratories Limited, launched Absorica (isotretinoin) 25 mg and 35 mg capsules into the US healthcare market. Absorica, according to the company, has become the most prescribe
- GSK Presents Updated Results from Phase III BREAK-3 Study of Tafinlar® (dabrafenib)https://practicaldermatology.com/news/20140929-gsk_presents_updated_results_from_phase_iii_break-3_study_of_tafinlar_dabrafenib/2459102/Results from the planned analysis of the Phase III BREAK-3 study in 250 patients with BRAF V600E mutant metastatic melanoma show benefit for the use of GSK's Tafinlar (dabrafenib) over dacarbazine (DTIC). Forty-five percent of patients treated with dabrafenib only were alive at two
- Provectus ESMO Presentation: Ablative, Bystander Effects Of PV-10https://practicaldermatology.com/news/20140929-provectus_esmo_presentation_ablative_bystander_effects_of_pv-10/2459103/Provectus Biopharmaceuticals, Inc.'s data featured in a presentation during the European Society For Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, show PV-10 has a higher rate of response in injected tumors through its ablative effect, and that the durability of response as well as the
- Foamix Pharmaceuticals Ltd. Closes Initial Public Offeringhttps://practicaldermatology.com/news/20140924-foamix_pharmaceuticals_ltd_closes_initial_public_offering/2459104/Foamix Pharmaceuticals Ltd. Closes Initial Public Offering A total of 6.7 million ordinary shares were sold at a price to the public of $6.00 per share. In addition, Foamix has granted the underwriters a 30 day option to purchase up to 1,005,000 additional ordinary shares. The sha
- Provectus: PV-10 Abstract Published; New Presentation Plannedhttps://practicaldermatology.com/news/20140924-provectus_pv-10_abstract_published_new_presentation_planned/2459106/The ESMO abstract entitled, "Subgroup efficacy in patients receiving intralesional rose bengal to all existing melanoma in phase II study PV-10-MM-02," to be presented at the European Society for Medical Oncology 2014 Congress, is now
- Provectus Biopharmaceuticals Appoints Christopher Kaplan to Its Strategic Advisory Boardhttps://practicaldermatology.com/news/20140922-provectus_biopharmaceuticals_appoints_christopher_kaplan_to_its_strategic_advisory_board/2459110/Christopher Kaplan, currently President of Cajetan, LLC, will now be appointed to Provectus Biopharmaceuticals Strategic Advisory Board. Mr. Kaplan started his pharmaceutical career at Bristol-Myers Squibb Company. He moved quickly through various roles in US sales and sales management and
- AppForMyPatients Now Available: Personalized Apps for Aesthetic Practiceshttps://practicaldermatology.com/news/20140922-appformypatients_now_available_personalized_apps_for_aesthetic_practices/2459112/A new patent pending mobile app Nano 2.0 Business Press, LLC aims to allow dermatologists and plastic surgeons to meet the growing patient demand for mobile applications. AppForMyPatients is a software as a service (saas) platform for d